Cell Type- and Phase-Dependent Immune Checkpoint Targeting in Sepsis: TIM-3 as a Model for Precision Immunomodulation.
- 1Department of Trauma Surgery, Emergency Surgery & Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Abstract
Sepsis is a dysregulated host response in which hyperinflammation, immunoparalysis, lymphoid depletion, myeloid dysfunction, tissue injury and defective pathogen control frequently coexist and evolve over time. Immune checkpoint pathways have therefore attracted interest as candidates for immune restoration, but receptor upregulation alone is an unreliable therapeutic signal. This review develops a cell type- and phase-dependent framework for immune checkpoint targeting in sepsis, using TIM-3 as a model checkpoint node. We first discuss the conceptual pitfalls in translating checkpoint blockade from cancer and chronic infection to acute heterogeneous sepsis. We then examine why the immune phase should be defined by dynamic host response states rather than by the clock time and why checkpoint signals must be interpreted according to their cellular source, including effector lymphocytes, NKT cells, CD4+ T cells, monocytes/macrophages, dendritic cells and suppressive myeloid populations. TIM-3 illustrates this complexity. In sepsis-relevant studies, TIM-3 has been linked to NKT cell and hepatic CD8+ T-cell apoptosis, CD4/HMGB1/TIM-3-associated hyporesponsiveness, Galectin-9-related ligand effects and potential myeloid or tissue-resident functions involving phosphatidylserine-positive debris, extracellular vesicles and tissue homeostasis. These observations argue against treating TIM-3 as a single-purpose inhibitory receptor or assuming that antibody blockade, ligand administration, receptor mutation and Galectin-glycan interference perturb the same biology. We propose that future checkpoint-directed studies should enroll immune states rather than syndromic sepsis alone; integrate the inflammatory burden, innate immune competence, lymphoid function and ligand context; and prioritize mechanistic endpoints such as lymphocyte apoptosis, IFN-γ recovery, monocyte HLA-DR restoration, LPS-induced TNF responses, bacterial clearance and secondary infection. Future precision immunomodulation studies in sepsis should evaluate defined checkpoint-associated circuits rather than infer therapeutic relevance from receptor expression alone.
Related
- Multi-omics insights into immune dysregulation and candidate biological programs in kawasaki disease: toward precision immunomodulation
- Moving Beyond the Plateau in Immune Checkpoint Inhibition-The Imperative of Early Referral and Precision Strategies.
- CCNE1 overexpression drives a cGAS-STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade.
- Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
- TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement
BibTeX
@article{luo2026cell,
title = {{Cell Type- and Phase-Dependent Immune Checkpoint Targeting in Sepsis: TIM-3 as a Model for Precision Immunomodulation.}},
author = {Jialiu Luo and Peidong Zhang and Shuaipeng Gu and Zhiqiang Lin and Yuhao Wu and Zhao-Hui Tang},
journal = {Pharmaceutics},
year = {2026},
month = oct,
doi = {10.3390/pharmaceutics18101343},
url = {https://europepmc.org/article/MED/42942872},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cell Type- and Phase-Dependent Immune Checkpoint Targeting in Sepsis: TIM-3 as a Model for Precision Immunomodulation.
AU - Jialiu Luo
AU - Peidong Zhang
AU - Shuaipeng Gu
AU - Zhiqiang Lin
AU - Yuhao Wu
AU - Zhao-Hui Tang
PY - 2026
DA - 2026/10/21
JO - Pharmaceutics
DO - 10.3390/pharmaceutics18101343
UR - https://europepmc.org/article/MED/42942872
AB - Sepsis is a dysregulated host response in which hyperinflammation, immunoparalysis, lymphoid depletion, myeloid dysfunction, tissue injury and defective pathogen control frequently coexist and evolve over time. Immune checkpoint pathways have therefore attracted interest as candidates for immune restoration, but receptor upregulation alone is an unreliable therapeutic signal. This review develops a cell type- and phase-dependent framework for immune checkpoint targeting in sepsis, using TIM-3 as a model checkpoint node. We first discuss the conceptual pitfalls in translating checkpoint blockade from cancer and chronic infection to acute heterogeneous sepsis. We then examine why the immune phase should be defined by dynamic host response states rather than by the clock time and why checkpoint signals must be interpreted according to their cellular source, including effector lymphocytes, NKT cells, CD4+ T cells, monocytes/macrophages, dendritic cells and suppressive myeloid populations. TIM-3 illustrates this complexity. In sepsis-relevant studies, TIM-3 has been linked to NKT cell and hepatic CD8+ T-cell apoptosis, CD4/HMGB1/TIM-3-associated hyporesponsiveness, Galectin-9-related ligand effects and potential myeloid or tissue-resident functions involving phosphatidylserine-positive debris, extracellular vesicles and tissue homeostasis. These observations argue against treating TIM-3 as a single-purpose inhibitory receptor or assuming that antibody blockade, ligand administration, receptor mutation and Galectin-glycan interference perturb the same biology. We propose that future checkpoint-directed studies should enroll immune states rather than syndromic sepsis alone; integrate the inflammatory burden, innate immune competence, lymphoid function and ligand context; and prioritize mechanistic endpoints such as lymphocyte apoptosis, IFN-γ recovery, monocyte HLA-DR restoration, LPS-induced TNF responses, bacterial clearance and secondary infection. Future precision immunomodulation studies in sepsis should evaluate defined checkpoint-associated circuits rather than infer therapeutic relevance from receptor expression alone.
SN - 1999-4923
ER -